Biocon’s arm gets USFDA’s nod for Dapagliflozin Tablets

08 Apr 2026 Evaluate

Biocon’s subsidiary -- Biocon Pharma has received approval from the U.S. Food and Drug Administration (USFDA) for Dapagliflozin Tablets, 5 mg and 10 mg. 

The approved product is indicated for the treatment of adults with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control, and reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular disease or multiple cardiovascular risk factors. This approval further strengthens Biocon’s expanding diabetes portfolio, which spans oral solid dosage formulations, biosimilar insulin, and complex GLP-1 peptides, reinforcing the Company’s integrated approach to addressing the evolving needs of people living with diabetes globally. Dapagliflozin Tablets will be manufactured at Biocon’s FDA-approved facilities, in compliance with global quality and regulatory standards.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide. 

Biocon Share Price

350.00 9.85 (2.90%)
08-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1713.60
Dr. Reddys Lab 1191.45
Cipla 1215.80
Zydus Lifesciences 891.55
Lupin 2293.55
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×